Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluconazole for congenital nephrogenic diabetes insipidus (AVPR2 mutation)
2020-002204-38Phase 2Active
- Sponsor
- Claus Bistrup
- Start
- May 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of fluconazole in congenital arginine vasopressin resistance (cAVP-R), sponsored by Claus Bistrup. Primary endpoint: Diuresis (mL/day). Started May 2020; status: active.
02
Drugs
fluconazole
03
Conditions
congenital arginine vasopressin resistance (cAVP-R)
Beyond the preview
Go deeper on 2020-002204-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002204-38.